Nitric oxide-dependent reduction in soluble guanylate cyclase functionality accounts for early lipopolysaccharide-induced changes in vascular reactivity - PubMed (original) (raw)

Nitric oxide-dependent reduction in soluble guanylate cyclase functionality accounts for early lipopolysaccharide-induced changes in vascular reactivity

Daniel Fernandes et al. Mol Pharmacol. 2006 Mar.

Abstract

We investigated the role of soluble guanylate cyclase in lipopolysaccharide-induced hyporesponsiveness to phenylephrine. The effects of phenylephrine on the blood pressure of female Wistar rats were evaluated at 2, 8, and 24 h after lipopolysaccharide injection (12.5 mg/kg i.p.). Vasoconstrictive responses to phenylephrine were reduced 40 to 50% in all time periods. Methylene blue, a soluble guanylate cyclase inhibitor (15 micromol/kg i.v.) restored the reactivity to phenylephrine in animals injected with lipopolysaccharide 2 and 24 h earlier. However, it failed to do so in animals injected with lipopolysaccharide 8 h earlier. Incubation with sodium nitroprusside (SNP) increased lung and aorta cGMP levels in control animals and in tissues of rats treated with lipopolysaccharide 24 h earlier. However, SNP failed to increase tissue cGMP in rats injected 8 h earlier. Lipopolysaccharide reduced the vasodilatory response to NO donors 8 h after injection. This effect and the decreased lung cGMP accumulation in response to SNP were reversed by an NO synthase blocker. Guanylate cyclase protein levels were lower than controls in lungs harvested from rats injected 8 h earlier and were back to normal values in lungs of rats injected 24 h earlier with lipopolysaccharide. Thus, data indicate that there is a temporal window of 8 h after lipopolysaccharide injection in which soluble guanylate cyclase is not functional and that this loss of function is NO-dependent. Thus, the putative use of soluble guanylate cyclase inhibitors in the treatment of endotoxemia may be beneficial mainly at early stages of this condition.

PubMed Disclaimer

Cited by

Early Use of Methylene Blue in Vasoplegic Syndrome: A 10-Year Propensity Score-Matched Cohort Study.
Kofler O, Simbeck M, Tomasi R, Hinske LC, Klotz LV, Uhle F, Born F, Pichlmaier M, Hagl C, Weigand MA, Zwißler B, von Dossow V. Kofler O, et al. J Clin Med. 2022 Feb 20;11(4):1121. doi: 10.3390/jcm11041121. J Clin Med. 2022. PMID: 35207394 Free PMC article.
Mechanisms of activity-dependent plasticity in cellular nitric oxide-cGMP signaling.
Halvey EJ, Vernon J, Roy B, Garthwaite J. Halvey EJ, et al. J Biol Chem. 2009 Sep 18;284(38):25630-41. doi: 10.1074/jbc.M109.030338. Epub 2009 Jul 15. J Biol Chem. 2009. PMID: 19605352 Free PMC article.
Methylene blue is not a pure vasoconstrictor drug.
Evora PR. Evora PR. Ann Card Anaesth. 2016 Apr-Jun;19(2):340-1. doi: 10.4103/0971-9784.179593. Ann Card Anaesth. 2016. PMID: 27052080 Free PMC article. No abstract available.
The role of potassium channels in the endothelial dysfunction induced by periodontitis.
Olchanheski LR Jr, Sordi R, Oliveira JG, Alves GF, Mendes RT, Santos FA, Fernandes D. Olchanheski LR Jr, et al. J Appl Oral Sci. 2018 Oct 4;26:e20180048. doi: 10.1590/1678-7757-2018-0048. J Appl Oral Sci. 2018. PMID: 30304126 Free PMC article.
The Rho-A/Rho-kinase pathway is up-regulated but remains inhibited by cyclic guanosine monophosphate-dependent mechanisms during endotoxemia in small mesenteric arteries.
da Silva-Santos JE, Chiao CW, Leite R, Webb RC. da Silva-Santos JE, et al. Crit Care Med. 2009 May;37(5):1716-23. doi: 10.1097/CCM.0b013e31819efb43. Crit Care Med. 2009. PMID: 19325475 Free PMC article.

Nitric oxide-dependent reduction in soluble guanylate cyclase functionality accounts for early lipopolysaccharide-induced changes in vascular reactivity - PubMed (original) (raw)